Form 4: Revance Therapeutics Officer Moxie Dwight Reports Stock Transactions
SEC Form 4 Filing
Dwight Moxie, CLO & GC of Revance Therapeutics, reports disposition of shares to cover tax obligations related to vesting restricted stock awards and performance-based restricted stock units.
Summary
- On March 15, 2024, Dwight Moxie surrendered 3,269 shares of Revance Therapeutics stock to cover tax obligations related to the vesting of a restricted stock award.
- These shares were surrendered at a price of $5.305 per share.
- On March 18, 2024, Moxie sold 8,125 shares at a weighted average price of $5.0426 to cover tax obligations related to the vesting of performance-based restricted stock units (PSUs).
- Following these transactions, Moxie directly owns 137,815 shares of Revance Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company officer to cover tax obligations. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.
Industry Context
Form 4 filings are a routine part of the stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock and future prospects. The transactions reported here are related to tax obligations arising from equity compensation, which is a common practice.
Comparison to Industry Standards
- Equity compensation is a standard practice in the biotechnology industry, often used to attract and retain talent.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize restricted stock units and performance-based awards as part of their compensation packages.
- The 'sell to cover' arrangement is a common mechanism to manage tax obligations associated with vesting equity, ensuring compliance and simplifying the process for employees.
Stakeholder Impact
- The transactions have a minimal direct impact on shareholders, as they are related to tax obligations and not discretionary trades.
- Employees who receive equity compensation may be affected by the stock price at the time of vesting, as it impacts the value of their awards.
Key Dates
| Date | Description |
|---|---|
| 03/15/2021 | Start date of the vesting of the restricted stock award (RSA) in three equal annual installments. |
| 01/31/2023 | Date of grant of performance-based restricted stock units (PSUs), which vest over a three-year period based on the achievement of revenue goals. |
| 03/15/2024 | Date of transaction where 3,269 shares were surrendered to cover tax obligations related to the vesting of a restricted stock award. |
| 03/18/2024 | Date of transaction where 8,125 shares were sold to cover tax obligations related to the vesting of performance-based restricted stock units (PSUs). |
| 03/19/2024 | Date of signature for the Form 4 filing. |
Keywords
Revance Therapeutics, RVNC, Form 4, Dwight Moxie, Stock Transaction, Restricted Stock Award, Performance-Based Restricted Stock Units, Tax Withholding, Sell to Cover
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.